Recombinant Glandirana rugosa Rugosin-B
Description
Antimicrobial Activity
Rugosin-B exhibits potent antibacterial activity, particularly against Gram-positive bacteria. Key findings include:
| Activity Profile | Gram-Positive | Gram-Negative | Fungi | Cancer Cells |
|---|---|---|---|---|
| Minimum Inhibitory Concentration (MIC) | 1–4 µg/mL | 8–16 µg/mL | 32 µg/mL | 16–32 µg/mL |
Recombinant Production and Challenges
While native Rugosin-B is isolated from frog skin secretions, recombinant production involves:
-
Cloning: Amplification of the precursor cDNA encoding preprobrevinin-2Rb, which includes a signal peptide, intervening sequence, and mature peptide .
-
Expression Systems: Likely use of bacterial (e.g., E. coli) or eukaryotic systems with codon optimization for efficient translation.
-
Post-Translational Modifications: Critical steps include disulfide bond formation and C-terminal amidation, often requiring specialized vectors or in vitro processing .
No explicit studies on recombinant Rugosin-B were identified in the provided sources, but methodologies for analogous AMPs (e.g., brevinin-2SSb) suggest feasibility .
The gene encoding Rugosin-B is conserved across Glandirana species, including G. rugosa, G. susurra, and G. emeljanovi. Phylogenetic analyses reveal:
-
Paraphyly in mitochondrial DNA lineages, suggesting rapid diversification of AMP genes .
-
Sex chromosome variations (ZW/ZZ systems) in G. rugosa correlate with AMP expression levels, though direct links to Rugosin-B remain unstudied .
